# Effect of Intranasal Insulin on POCD and POD

> **NCT03415061** · NA · UNKNOWN · sponsor: **Hiroaki Sato, MD., PhD.** · enrollment: 494 (estimated)

## Conditions studied

- Delirium
- Heart Diseases

## Interventions

- **DRUG:** Regular Insulin, Human 100 UNT/ML
- **DRUG:** Normal Saline Flush, 0.9% Injectable Solution

## Key facts

- **NCT ID:** NCT03415061
- **Lead sponsor:** Hiroaki Sato, MD., PhD.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 494 (ESTIMATED)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415061, "Effect of Intranasal Insulin on POCD and POD". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03415061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*